Scleroderma can harm the lungs and kidneys.
What is Scleroderma?
Chronic autoimmune condition scleroderma (systemic sclerosis) causes excess collagen formation by attacking connective tissues. This rare inflammatory condition hardens skin and can harm the lungs, kidneys, and heart. It is most common in women aged 30–50 and has no cure. Treatments manage symptoms and delay progression.
Types:
- Localised (morphea, linear) scleroderma primarily affects the skin and underlying tissues.
- Systemic sclerosis affects the skin, blood vessels, and organs. Subtypes:
- Limited cutaneous (CREST syndrome)—gradual onset, fingers, hands, and face.
- Fast-onset, extensive skin thickening, and increased risk of organ damage.
- Sine sclerosis—organ involvement without skin thickening.
Symptoms
- Skin: Tightness, shine, waxy areas, telangiectasia.
- In cold, Raynaud's phenomenon causes the fingers/toes to turn white or blue.
- Bloating, diarrhea, constipation, heartburn, and difficulty swallowing may also occur.
- Shortness of breath, pulmonary fibrosis, and hypertension may also occur.
- There is a risk of scleroderma renal crisis, which can lead to high blood pressure and kidney failure.
- Heart: Arrhythmias, failure, pericarditis.
- Joint/Muscle pain, stiffness, and inflexibility.
Causes and Risks
- Blood arteries are damaged by autoantibodies and T-cell abnormalities.
- Fibroblasts overproduce collagen and scar tissue.
Risk groups:
- Women (particularly 30–50).
- Africans and South Asians have worse illnesses.
- Vinyl chloride, epoxy resins, and aromatic hydrocarbons may cause it.
- Hormones and genetics may contribute.
Diagnosis
- Tests for diagnosis include blood tests for autoantibodies (ANA, anti-centromere, anti-Scl-70).
- CT, echocardiogram, and chest X-ray for lung/heart involvement.
- Biopsy: Tissue or skin.
- Lung function tests: Damage assessment.
Management & Treatment
- No cure—symptom control and progressive slowing.
- Medications:
- Methotrexate and mycophenolate are immunosuppressants.
- Vasodilators for Raynaud's.
- Renal crises: ACE inhibitors.
- Proton pump inhibitors for reflux.
- Phototherapy, physical therapy, and stem cell transplant in severe cases.
- Lifestyle: Stay warm, hydrate, exercise lightly, and control stress.
Complications major
- Skin, Vascular
- In difficult situations, Raynaud's can produce fingertip ulcers, pits, or tissue death.
- Digital ulcers and ischemia—pain, gangrene risk.
- Calcinosis—calcium deposits under the skin, posing an infection risk.
- Telangiectasia—dilated vessels cause red face/hands.
Lung involvement
- Interstitial lung disease (ILD)—scarring limits breathing.
- High lung artery pressure causes cardiac strain in pulmonary hypertension (PAH).
- Reduced exercise tolerance, shortness of breath due to progressive fibrosis.
Problems with the kidneys
- Rapid kidney failure and severe hypertension in scleroderma renal crisis.
- Must take ACE inhibitors immediately to avoid irreparable harm.
Problems with the heart
- Arrhythmias are irregular heartbeats.
- Scarred cardiac tissue causes heart failure.
- Inflammation of the heart sac—pericarditis.
The Digestion System
- Reflux, swallowing problems.
- Bowel issues—bloating, diarrhea, constipation, malabsorption.
- Anaemia, stomach bleeding from GAVE.
Dental, Joint Issues
- High decay, tight facial skin, tiny mouth opening, and poor oral care.
- Finger contractures resulted from joint rigidity.
Urgent Care Red Flags
- Raynaud's with fingertip ulcers worsening quickly.
- Unexpected hypertension or renal failure.
- Declining lung function causes breathlessness.
- An irregular heartbeat or chest discomfort.
- Undiagnosed anaemia or GI haemorrhage.
Scleroderma complication screenings
Scleroderma problems can be quiet, so doctors utilize screening tests to detect them early. Monitoring targets skin, vascular, lung, heart, kidney, and gastrointestinal systems.
Important Screening Tests
- Skin, Vascular
- Nailfold capillaroscopy—checks microscopic blood arteries for early injury.
- Assessing digital ulcers for ischemia and tissue loss.
lung involvement
- PFTs assess lung capacity and gas exchange.
- HRCT—detects interstitial lung disease (fibrosis).
- Echocardiogram—pulmonary hypertension screening.
Kidney Watching
- A frequent blood pressure assessment can detect renal crisis early.
- Test kidney function with serum creatinine and urinalysis.
Heart Screening
- ECG identifies arrhythmias.
- The echocardiogram measures heart function and pulmonary pressure.
- Detailed cardiac MRI for fibrosis or inflammation.
The Digestion System
- Checks for reflux or stomach vascular ectasia with endoscopy.
- Barium swallow—esophageal motility analysis.
- Tests for anemia following GI hemorrhage.
Scleroderma complication prevention
Scleroderma problems are prevented by early discovery, lifestyle changes, and organ-specific monitoring. To prevent life-threatening complications, Indian rheumatologists recommend lung and kidney screening, blood pressure control, and Raynaud's management.
Main Prevention Methods
- Skin, Vascular
- Wear gloves and warm clothes to avoid Raynaud's attacks.
- Stay away from smoking—it damages arteries.
- Regular wound care avoids digital ulcers and infections.
- Low-dose aspirin—may lower clot risk.
Lung protection
- Annual PFTs and HRCTs are recommended for early detection of fibrosis.
- Early reflux treatment minimizes aspiration and lung scarring.
- Influenza and pneumococcal immunizations prevent illnesses.
Kidney Watching
- Daily blood pressure checks—early renal crisis detection.
- Treat hypertension with ACE inhibitors immediately.
- Avoid high-dose steroids—renal crisis risk.
Heart Care
- Annual echocardiogram—pulmonary hypertension and fibrosis screenings.
- ECG monitoring—early arrhythmia detection.
- Gentle aerobic exercise promotes circulation.
The Digestion System
- PPIs prevent reflux issues.
- Small, frequent meals decrease reflux and bloating.
- Supplement iron and vitamins to prevent GI bleeding anemia.
Risks and Factors
- Delayed irreversible lung/kidney screening.
- Steroid abuse raises renal crisis risk.
- Poor adherence worsens results; patient education matters.
Systemic sclerosis treatments
Treating scleroderma involves managing fibrosis, vascular problems, and immunological activation. The latest worldwide guidelines (EULAR 2023) prescribe methotrexate, mycophenolate, rituximab, tocilizumab, and nintedanib for lung involvement. Although biologics are expensive, tertiary rheumatology institutes in India offer them.
Main Treatment Methods
- Skin Fibrosis
- Methotrexate—first-line for early-progressing cutaneous illness.
- Mycophenolate mofetil (MMF) treats skin and pulmonary fibrosis.
- Rituximab depletes B-cells, beneficial in refractory patients.
- Tocilizumab, an IL-6 blocker, may be effective for treating diffuse cutaneous illness.
- Localized skin thickening can be treated with UVA-1 phototherapy.
Interstitial lung disease
- Recommended first-line mycophenolate mofetil.
- An alternative for severe ILD: cyclophosphamide.
- Nintedanib slows lung fibrosis progression.
- Biologicals under trial for Rituximab/Tocilizumab show promise.
Vascular Issues
- For Raynaud's phenomenon, consider calcium channel blockers (amlodipine, nifedipine), PDE-5 inhibitors, and prostacyclin analogues.
- Infusions of bosentan and iloprost for digital ulcers.
- Combination therapy for pulmonary arterial hypertension (PAH) includes endothelin antagonists, PDE-5 inhibitors, and prostacyclin analogues.
- In acute renal crisis, ACE inhibitors (captopril, enalapril) are essential lifesaving treatments.
GI Symptoms
- For reflux and esophageal involvement, use proton pump inhibitors.
- Prokinetics for motility issues.
- In severe GI disease, nutrition is crucial.
Risks and Factors
- Immunosuppressants increase infection risk.
- Costly biologics (rituximab, tocilizumab) necessitate hospital supervision.
- Nintedanib may raise liver enzymes and cause diarrhea.
- Cyclophosphamide can cause bladder toxicity and infertility.
- AIIMS, CMC Vellore, and major rheumatology facilities in India offer biologics, which may require insurance or government programs.
Conclusion
Modern immunosuppressants, biologics, antifibrotics, and organ-specific therapy can improve outcomes, but there is no cure. Risk reduction requires screening, blood pressure monitoring, immunizations, and lifestyle changes.
Sudden hypertension, worsening Raynaud's, or inexplicable dyspnea must be detected early. Multidisciplinary treatment and proactive management can preserve quality of life and prevent irreversible damage.







